Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
WITHDRAWN
NCT07307768
PHASE1

Ketamine Biomarker Validation

Sponsor: Soterix Medical

View on ClinicalTrials.gov

Summary

An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.

Official title: EEG Biomarker Development for Ketamine Administration

Key Details

Gender

All

Age Range

18 Years - 59 Years

Study Type

INTERVENTIONAL

Enrollment

0

Start Date

2025-12-20

Completion Date

2028-03-01

Last Updated

2026-10-19

Healthy Volunteers

No

Interventions

DRUG

Ketamine (0.25 mg/kg)

Low level ketamine infusion therapy.

DRUG

Ketamine (0.5 mg/kg)

Medium level ketamine infusion therapy.

DRUG

Ketamine (0.75 mg/kg)

High level ketamine infusion therapy.

Locations (1)

Columbia University Irving Medical Center

New York, New York, United States